Skip to main content

Table 2 Clinicopathologic characteristics according to protein expression and genetic alteration of PD-L1 and STAT3 activation in EBV-negative diffuse large B cell lymphoma patients

From: Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

Clinicopathologic characteristics

PD-L1 expression in tumor cells (PD-L1t)

PD-L1 expression in immune cells (PD-L1i)

PD-L1 genetic alteration in tumor cells (PD-L1 GA)

pSTAT3a expression in tumor cells

PD-L1t−

PD-L1t+

p value

PD-L1i−

PD-L1i+

p value

PD-L1 GA−

PD-L1 GA+

p value

pSTAT3−

(< 40%)

pSTAT3+

(> 40%)

p value

Age

 ≤ 60

40 (48%)

13 (57%)

0.449#

38 (55%)

15 (39%)

0.122#

43 (47%)

7 (70%)

0.196†

34 (54%)

19 (43%)

0.272#

 > 60

44 (52%)

10 (43%)

 

31 (45%)

23 (61%)

 

49 (53%)

3 (30%)

 

29 (46%)

25 (57%)

 

Sex

 Male

49 (58%)

12 (52%)

0.597#

40 (58%)

21 (55%)

0.787#

52 (57%)

6 (60%)

1.000†

33 (52%)

28 (64%)

0.247#

 Female

35 (42%)

11 (48%)

 

29 (42%)

17 (45%)

 

40 (43%)

4 (40%)

 

30 (48%)

16 (36%)

 

Primary site

 Nodal

44 (52%)

10 (43%)

0.449#

33 (48%)

21 (55%)

0.462#

50 (54%)

2 (20%)

0.049†

27 (43%)

27 (61%)

0.060#

 Extranodal

40 (48%)

13 (57%)

 

36 (52%)

17 (45%)

 

42 (46%)

8 (80%)

 

36 (57%)

17 (39%)

 

B symptoms

 Absent

68 (81%)

17 (74%)

0.561†

55 (80%)

30 (79%)

0.926#

77 (84%)

6 (60%)

0.087†

48 (76%)

37 (84%)

0.320#

 Present

16 (19%)

6 (26%)

 

14 (20%)

8 (21%)

 

15 (16%)

4 (40%)

 

15 (24%)

7 (16%)

 

ECOG PS

 < 2

77 (92%)

20 (87%)

0.445†

61 (88%)

36 (95%)

0.489†

85 (92%)

8 (80%)

0.214†

56 (89%)

41 (93%)

0.520†

 ≥ 2

7 (8%)

3 (13%)

 

8 (12%)

2 (5%)

 

7 (8%)

2 (20%)

 

7 (11%)

3 (7%)

 

Serum lactate dehydrogenasea

 Normal

45 (56%)

9 (39%)

0.164#

34 (52%)

20 (53%)

0.913#

47 (51%)

5 (50%)

1.000†

32 (52%)

22 (49%)

0.896#

 Elevated

36 (44%)

14 (61%)

 

32 (48%)

18 (47%)

 

42 (49%)

5 (50%)

 

29 (48%)

21 (51%)

 

No. of extranodal sites

 < 2

65 (77%)

16 (70%)

0.439#

54 (78%)

27 (71%)

0.405#

71 (78%)

5 (50%)

0.118†

51 (81%)

30 (68%)

0.130#

 ≥ 2

19 (23%)

7 (30%)

 

15 (22%)

11 (29%)

 

21 (22%)

5 (50%)

 

12 (19%)

14 (32%)

 

Ann Arbor stage

 I–II

45 (54%)

11 (48%)

0.625#

38 (55%)

18 (47%)

0.445#

50 (%)

5 (50%)

1.000†

37 (59%)

19 (43%)

0.113#

 III–IV

39 (46%)

12 (52%)

 

31 (45%)

20 (53%)

 

42 (%)

5 (50%)

 

26 (41%)

25 (57%)

 

International prognostic index

 0–2

57 (68%)

14 (61%)

0.530#

47 (68%)

24 (63%)

0.603#

64 (70%)

5 (50%)

0.286†

44 (70%)

27 (61%)

0.361#

 3–5

27 (32%)

9 (39%)

 

22 (32%)

14 (37%)

 

28 (30%)

5 (50%)

 

19 (30%)

17 (39%)

 

Bone marrow involvementa

 Absent

66 (87%)

18 (82%)

0.553†

54 (86%)

30 (86%)

1.000

76 (89%)

7 (70%)

0.283†

51 (88%)

33 (83%)

0.450#

 Present

10 (13%)

4 (18%)

 

9 (14%)

5 (14%)

 

9 (11%)

2 (20%)

 

7 (12%)

7 (17%)

 

Bulky mass (cm)

 < 10

78 (93%)

20 (87%)

0.401†

64 (93%)

34 (89%)

0.718†

84 (91%)

9 (90%)

1.000†

56 (89%)

42 (95%)

0.302†

 ≥ 10

6 (7%)

3 (13%)

 

5 (7%)

4 (11%)

 

8 (9%)

1 (10%)

 

7 (11%)

2 (5%)

 

Hans classificationa

 GCB

26 (34%)

1 (5%)

0.006†

20 (32%)

7 (19%)

0.186

26 (30%)

0 (0%)

0.058†

20 (35%)

7 (17%)

0.042#

 Non-GCB

51 (66%)

21 (95%)

 

43 (68%)

29 (81%)

 

61 (70%)

10 (100%)

 

37 (65%)

35 (83%)

 

BCL2 expressiona

 Negative

33 (40%)

8 (35%)

0.665#

31 (46%)

10 (26%)

0.051#

35 (38%)

2 (20%)

0.321†

31 (50%)

10 (23%)

0.004#

 Positive

50 (60%)

15 (65%)

 

37 (54%)

28 (74%)

 

57 (62%)

8 (80%)

 

31 (50%)

34 (77%)

 

BCL6 expression

 Negative

43 (51%)

17 (74%)

0.052#

36 (52%)

24 (63%)

0.273#

46 (50%)

9 (90%)

0.019†

39 (62%)

21 (48%)

0.146#

 Positive

41 (49%)

6 (26%)

 

33 (48%)

14 (37%)

 

46 (50%)

1 (10%)

 

24 (38%)

23 (52%)

 

CD10 expression

 Negative

69 (82%)

23 (100%)

0.037†

57 (83%)

35 (92%)

0.248†

77 (84%)

10 (100%)

0.351†

52 (83%)

40 (91%)

0.268†

 Positive

15 (18%)

0 (0%)

 

12 (17%)

3 (8%)

 

15 (16%)

0 (0%)

 

11 (17%)

4 (9%)

 

MUM1 expression

 Negative

36 (43%)

5 (22%)

0.065#

28 (41%)

13 (34%)

0.517#

35 (38%)

1 (10%)

0.094†

31 (49%)

10 (23%)

0.006#

 Positive

48 (57%)

18 (78%)

 

41 (59%)

25 (66%)

 

57 (62%)

9 (90%)

 

32 (51%)

34 (77%)

 

Total N (%)

84 (100%)

23 (100%)

 

69 (100%)

38 (100%)

 

92 (100%)

10 (100%)

 

63 (100%)

44 (100%)

 
  1. NA: not applicable; ECOG PS: the Eastern Cooperative Group Performance Status; GCB: germinal center B-cell like; R-CHOP: rituximab with cyclophosphamide–doxorubicin–vincristine–prednisone; GI: gastrointestinal; GA: genetic alteration; IHC: immunohistochemistry; SD: standard deviation
  2. aThese variables excluded unclassifiable (or unknown) cases
  3. p values were calculated by using Fisher’s exact test (2-sided)† or Pearson’s Chi square test (2-sided)#
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us